DelveInsight's“ Chikungunya Pipeline Insight 2025 ” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Chikungunya pipeline landscape. It covers the Chikungunya Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chikungunya Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chikungunya Pipeline? Click here to explore the therapies and trials making headlines @ Chikungunya Pipeline Outlook Report

Key Takeaways from the Chikungunya Pipeline Report

• In August 2025, Valneva Austria GmbH conducted a clinical trial will be to evaluate persistence of antibodies annually from 1 to 10 years after the single immunization with VLA1553. The secondary objective is to evaluate long-term safety 6 months to 2 years after the single immunization with VLA1553.
• DelveInsight's Chikungunya Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Chikungunya treatment.
• The leading Chikungunya Companies such as Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.
• Promising Chikungunya Pipeline Therapies such as MV-CHIK, MMR-vaccine, VLA1553, V184 , and others.

Want to know which companies are leading innovation in Chikungunya? Dive into the full pipeline insights @ Chikungunya Clinical Trials Assessment

The Chikungunya Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chikungunya Pipeline Report also highlights the unmet needs with respect to the Chikungunya.

Chikungunya Overview

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes, and is responsible for causing Chikungunya fever-an acute febrile illness marked by high fever, maculopapular rash, myalgia, and, most notably, severe and often incapacitating arthralgia. The name ""Chikungunya"" is derived from the Makonde language, meaning ""to become contorted,"" reflecting the stooped posture of sufferers due to joint pain. While the acute phase of the illness typically resolves within a week, a significant number of patients develop chronic, relapsing arthritis or arthralgia that can persist for months or even years, mimicking inflammatory rheumatic conditions.

Chikungunya Emerging Drugs Profile

• HydroVax-005 CHIKV: Najit Technologies, Inc.

HydroVax-005 CHIKV, developed by Najit Technologies, Inc., is an investigational inactivated vaccine candidate for the prevention of chikungunya virus (CHIKV) infection. The vaccine utilizes a novel site-directed hydrogen peroxide-based inactivation method (the HydroVax platform) that preserves key neutralizing epitopes on the virus, resulting in robust immune responses and protection in preclinical models, outperforming traditional inactivation techniques like heat or UV that can damage these epitopes. Currently, the drug is in the Phase I stage of its development for the treatment of Chikungunya.

If you're tracking ongoing Chikungunya Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Chikungunya Treatment Drugs

The Chikungunya Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Chikungunya with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chikungunya Treatment.
• Chikungunya Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chikungunya Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chikungunya market.

Chikungunya Companies

Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.

Chikungunya Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chikungunya Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Chikungunya Pipeline Report covers it all – check it out now @ Chikungunya Market Drivers and Barriers, and Future Perspectives

Scope of the Chikungunya Pipeline Report

• Coverage- Global
• Chikungunya Companies- Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.
• Chikungunya Pipeline Therapies such as MV-CHIK, MMR-vaccine, VLA1553, V184 , and others.
• Chikungunya Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chikungunya Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Chikungunya Treatment landscape in this detailed analysis @ Chikungunya Emerging Drugs and Major Players

Table of Contents